1	Title page
2	
3	Acceptance of COVID 19 vaccine among sub-
4	Sahara African (SSA): a comparative study of
5	residents and diaspora dwellers
6	
7	
8	Chundung Asabe Miner ¹ , Chikasirimobi G. Timothy ² , Khathutshelo Percy
9	Mashige ³ ¶, Uchechukwu Levi Osuagwu ⁴ ¶*, Esther Awazzi Envuladu ^{5&} , Onyekachukwu
10	Mary-Anne Amiebenomo ^{6#a&} , Godwin Ovenseri-Ogbomo ^{7&} , Deborah Donald Charwe ^{8&} ,
11	Piwuna Christopher Goson ⁹ , Bernadine N Ekpenyong ¹⁰ , Emmanuel Kwasi Abu ¹¹ ,
12	Raymond Langsi ^{12&} , Richard Oloruntoba ^{13&} , Tanko Ishaya ^{14&} , , Kingsley Agho ¹⁵
13	
15	
14	¹ Department of Community Medicine, College of Health Sciences, University of Jos, Jos,
15	Plateau State, Nigeria
16	² Department of Optometry and Vision Sciences, School of Public Health, Biomedical
17	Sciences and Technology, Masinde Muliro University of Science and Technology,
18	Kakamega, Kenya ³ African Vision Research Institute (AVRI), School of Health Sciences, University of
19 20	KwaZulu-Natal, Durban, South Africa
20	⁴ Translational Health Research Unit (THRI), School of Medicine, Western Sydney
22	University, Campbelltown, Australia
23	⁵ Department of Community Medicine, College of Health Sciences, University of Jos, Jos,
24	Nigeria
25	⁶ Department of Optometry, Faculty of Life Sciences, University of Benin, Ugbowo, Benin
26	City, Nigeria
27	⁷ Department of Optometry, Centre for Health Sciences, University of the Highlands and
28	Islands, Inverness, UK
29	⁸ Tanzania Food and Nutrition Center, Dar-es-Salaam, Tanzania
30	⁹ Department of Psychiatry, College of Health Sciences, University of Jos, Jos, Plateau State,
31	Nigeria
32	¹⁰ Department of Public Health, Faculty of Allied Medical Sciences, College of Medical
33	Sciences, University of Calabar, Calabar, Cross River State, Nigeria
34	¹¹ Department of Optometry and Vision Science, School of Allied Health Sciences, College of
35	Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana
36	¹² Health Division, University of Bamenda, Bambili, Cameroon NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 38 39 40 41 42 43	 ¹³School of Management and Marketing, Curtin Business School, Curtin University, Bentley, Australia ¹⁴Department of Computer Science, University of Jos, Jos, Nigeria ¹⁵School of Health Science, Western Sydney University, Campbelltown, Australia; ^{#a} Current address: School of Optometry and Vision Sciences, College of Biomedical Sciences, Cardiff University, Cardiff, United Kingdom
44	*Corresponding author:
45	Email: l.osuagwu@westernsydney.edu.au (ULO)
46	
47	[¶] These authors contributed equally to this work
48	^{&} These authors also contributed equally to this work
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	

3

64 Abstract

65

The COVID-19 vaccines are being rolled out across all the Sub-Saharan Africa (SSA) 66 countries, with countries setting targets for achieving full vaccination rates. The aim of this 67 study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between 68 SSA locally residents and in the diaspora. This was a cross-sectional study conducted using a 69 70 web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine acceptance. The survey items included questions on demography, uptake and planned 71 acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic 72 regression was used to determine probabilities of outcomes for factors associated with COVID-73 19 vaccination resistance and hesitancy among SSA respondents residing within and outside 74 Africa. Uptake of COVID-19 vaccines varied among the local (14.2%) and diaspora (25.3%) 75 residents. There was more resistance to COVID-19 vaccine among locals (68.1%) and across 76 77 the sociodemographic variables of sex [adjusted Relative Risk (ARR) =0.73, 95% CI; 0.58 -0.93], primary/less [ARR =0.22, 95% CI; 0.12 – 0.40] and bachelor's degree [ARR =0.58, 95% 78 CI; 0.43 - 0.77] educational levels, occupation [ARR = 0.32, 95% CI; 0.25 - 0.40] and working 79 80 status [ARR =1.40, 95%CI; 1.06 - 1.84]. COVID-19 vaccine hesitancy was almost similar between locals and diasporas (17.7% and 17.8% respectively) significant only among 81 healthcare workers [ARR = 0.46, 95% CI; 0.16 - 1.35] in the diaspora after adjusting for the 82 variables. Similarly, knowledge and perception of COVID-19 vaccine among locals were 83 substantial, but only perception was remarkable to resistance [ARR =0.86, 95% CI; 0.82 -84 85 (0.90] and hesitancy [ARR = 0.85, 95% CI; (0.80 - 0.90] of the vaccine. Differences exist in the factors that influence COVID-19 vaccine acceptance between local SSA residents and those in 86 the diaspora. Knowledge about COVID-19 vaccines affects the uptake, resistance, and 87 88 hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety of vaccines could lead to improved acceptance of COVID-19 vaccines. 89

4

90 Keywords: Vaccination; Acceptance; COVID-19; Hesitancy; Resistance; Sub-Sahara Africa;
91 Locals; Diaspora

- 92 Running title: COVID-19 vaccine uptake, resistance, hesitancy
- 93

94 Introduction

95

The coronavirus disease (COVID-19) pandemic that started in December of 2019, 96 initially reported in Wuhan, China, has continued despite preventative measures adopted 97 98 worldwide under the guidance of the World Health Organization (WHO). Many countries have experienced their second, third and fourth waves in terms of cases and resultant 99 deaths.[1-4] The outbreak of the new Omicron variant in different countries [5-7] is of global 100 101 concern.[8] as it threatens the return to normalcy and the ongoing COVID-19 vaccination programmes. Non-pharmaceutical interventions to minimise the spread of infections included 102 travel restrictions, lockdowns, physical distancing, regular handwashing and wearing of face 103 masks.[9-10] From the onset of the pandemic, scientists and pharmaceutical companies began 104 the development of COVID-19 vaccines to offer protection against severe disease.[11] 105 The Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, 106 Sinopharm/BIBP and India's Covishield, [12-13] vaccines are licensed for use across the 107 globe. The utilisation of any vaccine can be influenced by system, client and provider 108 109 factors, [14] but in particular, vaccine acceptance plays a huge role for clients and providers. Generally, the acceptance of any vaccine has been shown to be influenced by demographic 110 factors, knowledge of the disease and the consequences of contracting it, perceptions of 111 susceptibility, potential benefits of a health action and the occurrence of one or more cues to 112 action.[11-17] Similar factors may influence COVID-19 vaccine acceptance. 113

5

The COVID-19 vaccines have shown to be efficient and safe,[18] however, their 114 acceptance is a major barrier to the successful rollout plans in different countries including 115 the SSA region. This is further exacerbated by the mistrust in the government demonstrated 116 by residents in this region.[19] The WHO defines vaccine hesitancy as a 'delay in acceptance 117 or refusal of safe vaccines despite availability of vaccine services'[20] It is also stated to be 118 one of the top ten threats to global health.[21-22] Vaccine hesitancy is used to describe a 119 phenomenon where individuals are unsure of getting vaccinated. Those who object to getting 120 the vaccine are defined as vaccine resistant. [23] 121

The success of vaccines depends on achieving maximum coverage and thereby attaining herd immunity.[24] Vaccine acceptance is therefore crucial to the efforts currently made by public health experts of ensuring that the communities in every country are fully vaccinated. Studies have shown that there have been disparities in vaccine acceptance for other conditions, and factors such as age, race and ethnicity, social class, country and region of origin were associated with acceptance of vaccines.[25-26] Similar results were reported for COVID-19 vaccines.[27-28]

Persons in the diaspora are "national migrant communities living in interaction among 129 themselves and with their country of origin".[29] Africans in the diaspora have been referred 130 to by the African Union as "people of African origin living outside of the continent, 131 irrespective of their citizenship and nationality, and who are willing to contribute to the 132 133 development of the continent and the building of the African Union".[30] It is generally believed that being in the diaspora provides Africans with greater opportunities to become 134 more enlightened and therefore adopt different approaches to decision making.[30] 135 Furthermore, studies have shown that there is geographical and spatial variation in the uptake 136 of vaccines.[31-32] In SSA, access to COVID-19 vaccines have improved, but the 137 availability of vaccines and uptake remains substantially low compared with the rich 138

6

European and North-American countries [33], and only 11% of the adult population in Africa 139 are fully vaccinated as at January 2021.[34] Although there are significant differences in the 140 vaccination programmes and their rollout between countries, [35-36] the fact that a previous 141 study found similarities in the attitude and risk perception towards COVID-19 among 142 Africans living locally and those in the diaspora (mostly living in Western countries) during 143 the lockdown, [37] suggests there could be similarities in their acceptance of the COVID-19 144 vaccination. This study, therefore, sought to investigate the differences in the acceptance of 145 COVID-19 vaccination of Sub-Sahara Africans living on the African continent and those in 146 147 the diaspora. Although different studies exist that looked at COVID-19 vaccine acceptance, none had compared the same between locals and diaspora dwellers in SSA at the time of this 148 study. 149

150 Methods

151 Ethics and consent

Ethical approval to conduct the study was obtained from the Humanities and Social Sciences Research Ethics Committee (approval #: HSSREC 00002504/2021) of the University of KwaZulu-Natal, Durban, South Africa. The study adhered to the tenets of the Declaration of Helsinki involving human participants [38], and anonymous voluntary informed consent was obtained from all participants as part of the preamble accompanying the questionnaire.

Participants were included in this study if they were of African origin, aged 18 years and older, and provided consent. Completion of the questionnaire was only possible after the participants had responded to the consent question, 'do you voluntarily take part in this study?' Those who answered 'No' to this question were automatically locked out from the survey platform.

7

163 Study setting and population

- 164 The study population included adults who were 18 years and older and were of sub-
- 165 Saharan Africans residing locally (in Africa) and in diaspora (outside of Africa). Respondents
- 166 from several countries in SSA, mostly from Cameroun, Ghana, Nigeria, South Africa,
- 167 Tanzania, and those in diaspora mostly living in Australia, United Kingdom, United States,

168 Saudi Arabia, Canada, China, and India took part in this study.

169 Sample size determination

The sample size was determined using Cochran's formulae ($n = z^2 pq/d^2$) with the assumption of a proportion of 50% at a confidence level of 95% with an error margin of 2.5%. A 20% non-response rate was assumed, and a minimum sample size of 2401 was obtained.

174 Study design

This was a web-based cross-sectional survey carried out between 14th of March and 176 17th of May 2021. Due to the continued COVID-19 lockdowns in many of the target 177 countries at the time of this study, web-based study was most appropriate even though it may 178 have excluded some participants with no access to internet-based phone/computer services.

179 The survey instrument and data collection

Data was collected using a validated self-administered questionnaire adapted from a previous study.[39] The survey tool was tested for the internal validity of the items, and Cronbach's alpha coefficient score ranged from 0.70 and 0.74, indicating satisfactory consistency.[40] The questionnaire was designed on survey monkey in both English and French, which are spoken languages in 26 and 21 SSA countries, respectively.[41] The questionnaire was disseminated electronically through an e-link on social media networks such as WhatsApp, Facebook and e-mail. There was an accompanying introductory section

that included the background and goal of the study, procedure for participation and informed
consent guide. Participants were requested on the introductory page not to participate in the
survey more than once.

190 **Confounding variables**

191 The survey instrument showing the various variables collected has been presented in

the Supporting information (S1 Table). The independent variables included

sociodemographic variables; age, gender, region, marital status, the highest level of

education, occupation, employment status, religion, smoking status, previous vaccination for

other conditions and pre-existing medical conditions; knowledge of COVID-19 vaccines;

196 perception of risk for contracting COVID-19; and attitude towards vaccination for COVID-

197 19 (S1 Table). The exposure variable was the 'place of residence' (local or diaspora).

The COVID-19 vaccine knowledge items had 10 questions on a Likert scale with five levels as indicated in SI Table 1. The scores for nine of the items ranged from 0 (lowest) to 4 (highest) while, for one item, it was coded as 1 for Yes and 0 for No. The overall knowledge towards COVID-19 vaccination score ranged from 0 -37 points, with a higher knowledge score indicating a better knowledge towards COVID-19 vaccination.

The attitude towards the COVID-19 vaccine items included four items with each assigned 2 points for 'yes', 1 point for 'unsure' and 0 point for 'No'. The total attitude score ranged from 0 to 8, with a higher score denoting a better attitude towards COVID-19 vaccination.

The risk perception for contracting the disease after vaccination included questions on how the participants rate their risk of becoming infected with the virus and risk of dying from the infection. The responses were structured using a Likert scale with five levels (S1 Table), with scores for each item ranging from 0 (lowest) to 4 (highest). The total perception score

9

ranged from 0 to 8, with a higher score representing a higher perception of contracting theinfection following COVID-19 vaccination.

213 Main outcome variables

The main outcomes were vaccine uptake, resistance and hesitancy. Uptake was

determined by answering 'yes' to the question "Have you been vaccinated against COVID-

216 *19?*". The vaccine resistant group were those that answered 'no' to the question '*Will you be*

willing to be vaccinated against COVID-19 if the vaccine becomes available in your

country?', while those who answered 'not sure' were defined as the vaccine 'hesitant' group.

Data analysis

Data were analyzed using STATA/MP version 14 (Stata Corp 2015, College Station, 220 TX, USA. A 95% confidence interval (CI) was set for this survey, and a p-value of <0.05 was 221 considered statistically significant. Descriptive data were summarized and presented in tables 222 and charts using frequencies, percentages, mean and standard deviations as required. 223 Multinomial logistic regression analyses were used to examine the COVID-19 vaccination 224 status on sources of information. As part of the multiple multinomial logistic regression 225 analyses, a staged modelling technique was carried out. Elimination method was conducted 226 using multiple multinomial logistic regression modelling techniques to remove statistically 227 non-significant variables. Demographic factors were first entered into the baseline multiple 228 regression model, followed by health indicators factors and the exposure variables were 229 examined in the final model, which also included knowledge, attitude and risk perception 230 variables, keeping only those variables significant in the previous model. In the final model, 231 we tested and reported any co-linearity. The relative risk with 95% confidence intervals were 232 233 calculated to assess the adjusted risks of independent variables.

10

235 **Results**

236 Characteristics of the respondents

237	There was a total of 2545 SSA respondents [2391 locals (93.9%) and 154 in the
238	diaspora (6.1%)]. Table 1 shows the frequency and percentage distribution of respondents
239	according to their socio-demographic variables. The majority of the SSA local residents
240	(67.8%) were younger than 38 years, while those in the diaspora were older. There were more
241	females than males in both groups, and the majority were originally from West Africa (locals
242	55.6%, diaspora 75.4%). More than half (56.9%) of the locals were not married, and 59.7%
243	from the diaspora were married. Many locals had a bachelors' degree (56.9%), and most
244	diaspora participants were postgraduate degree holders (53.3%). Most respondents from both
245	groups were employed /self-employed were predominantly non-healthcare workers and were
246	of the Christian faith. More than 80% of locals and above 90% of those in the diaspora had
247	been previously vaccinated for one or two other conditions. More than two-thirds of the
248	respondents indicated that they have never smoked. The proportion of respondents with
249	preexisting conditions was high among locals (84.6%) and diaspora (69.5%).

Table 1: Characteristics (n=2545) of the study participants living in (Local) and outside of Africa (Diaspora).

Variables	Local	Diaspora
	2391 (93.9%)	154 (6.1)
Age group (years)		
18 – 28	898 (38.7)	23 (14.9)
29-38	677 (29.1)	41 (26.6)
39 - 48	450 (19.4)	46 (29.9)
49 +	297 (12.8)	44 (28.6)
Sex	I	
Males	1,264 (52.9)	112 (72.7)
Females	1,127 (47.1)	42 (27.7)
SSA region of origin*	· · · ·	
West Africa	1,330 (55.6)	107 (75.4)
East Africa	116 (4.9)	6 (4.2)
Central Africa	288 (12.1)	24 (16.9)

Southern Africa	657 (27.5)	5 (3.5)	
Marital status			
Married	1,030 (43.1)	92 (59.7)	
Not married ‡	1,361 (56.9)	62 (40.3)	
Highest level of education			
Postgraduate degree	668 (27.9)	82 (53.3)	
(Masters/PhD)			
Bachelor's degree	1,237 (51.7)	61 (39.6)	
Secondary/High School	436 (18.2)	9 (5.8)	
Primary or Less	50 (2.1)	2 (1.3)	
Employment status	I		
Employed/Self employed	1,733 (72.5)	139 (90.3)	
Unemployed/Retired	658 (27.5)	15 (9.7)	
Religion	I		
Christianity	2,140 (89.5)	138 (89.6)	
Others	251 (10.5)	16 (10.4)	
Occupation			
Non-Healthcare	1,658 (69.3)	95 (61.7)	
Healthcare	733 (30.7)	59 (38.3)	
Previous vaccination for any condi	tion		
No	430 (18.0)	15 (9.7)	
Yes	1,961 (82.0)	139 (90.3)	
Smoking Status			
Ex-smoker	142 (5.9)	18 (11.7)	
Current smoker	168 (7.0)	8(5.2)	
Non smoker	2,081 (87.0)	128 (83.1)	
Risk factors: Any pre-existing cond	lition [§]		
No	2,022 (84.6)	107 (69.5)	
Yes	369 (15.4)	47 (30.5)	

253 Data presented as frequencies (percentages)

254 *SSA; Sub-Sahara Africa, *includes single, divorced, and widowed*

§includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney 255

256 disease, any heart condition, sickle cell anemia

257

Prevalence of uptake, resistance and hesitancy towards COVID-258 19 vaccine in SSA 259

Figure 1 presents the prevalence of vaccine uptake, resistance and hesitancy in both 260

- locals and those in the diaspora. The prevalence of COVID-19 vaccine uptake respondents 261
- was almost twice higher among the diaspora (25.3%) than among the locals (14.2%). 262
- Resistance to the COVID-19 vaccine was more common among the locals (68.1%) than those 263
- in the diaspora (55.2%). Hesitancy to COVID-19 vaccine was almost the same for both locals 264
- and resident in the diaspora(See Figure 1). 265

266

Fig I: Prevalence and 95% confidence intervals of vaccine uptake, resistance and hesitancy 267 among SSAs living in (within) and outside of Africa (diaspora). 268

269

Distribution of vaccine uptake, resistance and hesitancy among 270 local and diaspora residents 271

Table 2 shows the variations in the distribution of vaccine uptake, resistance and 272 hesitancy across the demographic variables as well as their mean scores for knowledge, 273 274 attitude and perception of risk of infection. Those aged between 39 - 48 years had the highest proportion of locals that were resistant to the vaccine (70.0%) while among those in the 275 diaspora, the 18 - 28 years' age range had the highest proportion (73.9%). More males 276 (70.2%) than females (65.7%) were resistant to taking the vaccine among the locals, whereas 277 there was a preponderance of resistant females in the diaspora group (64.3%). 278

279 COVID-19 vaccine uptake was highest among Central African residents (20.1%) who lived locally but was highest among West Africans (29.9%) in the diaspora. The uptake of 280 COVID-19 vaccine had the highest proportion among those with primary/less education [19 281 (38%)] while among those in the diaspora, uptake was highest in those having a Master's 282 degree and higher [22 (26.8%)]. Resistance was substantial in those with Master's and higher 283 degree respondents (70.7% for locals and 51.2% for those in the diaspora). For both 284 285 healthcare and non-healthcare workers in both groups, the greatest proportions were resistant to taking the vaccine. The proportion of uptake, hesitancy and resistance towards COVID-19 286 vaccines varied with the employment status of the respondents, though the unemployed had 287 the highest proportions of vaccine resistance in both groups (72.6% for locals and 60.0% for the 288 diaspora). Christians represented the higher number of those who said they were hesitant to 289 290 take the vaccine (18.6%) as compared with non-Christians in the diaspora (31.3%). Those who were ex-smokers had the highest proportion of those who were resistant among both the 291

13

locals (69.0%) and those in the diaspora (72.2%). The uptake of the vaccine was also higher

among those with pre-existing conditions in both local and diaspora respondents.

Higher mean scores for attitude and perception were observed among the COVID-19

- vaccine uptake respondents for the local residents, while the mean knowledge score was
- highest for the hesitant group. Among the diasporas, the mean knowledge and perception
- scores were similarly highest in uptake respondents, but a higher score for attitude was
- 298 observed in the hesitancy respondents (Table 2).

Table 2. Prevalence of vaccine uptake, hesitancy and resistance among SSAs living in (local) and outside Africa (diaspora).

		LOCAL			DIASPOR	
Variable					Α	
variable	Uptake	Resistant	Hesitant	Uptake	Resistant	Hesitant
	n = 340	n = 1627	n = 424	n = 39	n = 85	n = 30
Age in years						
18 - 28	127 (14.1)	621 (69.2)	150 (16.7)	2 (8.7)	17 (73.9)	4 (17.0)
29 - 38	101 (14.9)	435 (64.3)	141 (20.8)	3 (7.3)	25 (61.0)	13 (31.0)
39 - 48	61 (13.6)	315 (70.0)	74 (16.4)	18 (39.1)	20 (43.5)	8 (17.0)
49+	33 (11.1)	205 (69.0)	59 (19.9)	16 (36.4)	23 (52.3)	5 (11.0)
Sex						
Males	159 (12.6)	887 (70.2)	218 (17.3)	32 (28.6)	58 (51.8)	22 (19.6)
Females	181 (16.1)	740 (65.7)	206 (18.3)	7 (16.7)	27 (64.3)	8 (19.1)
Region						
West Africa	205 (15.4)	897 (67.4)	228 (17.1)	32 (29.9)	54 (50.5)	21 (19.6)
East Africa	6 (5.2)	80 (69.0)	30 (25.9)	0 (0.0)	3 (50.0)	3 (50.0)
Central Africa	58 (20.1)	186 (64.6)	44 (15.3)	6 (25.0)	16 (66.7)	2 (8.3)
Southern Africa	71 (10.8)	464 (70.6)	122 (18.6)	0 (0.0)	4 (80.0)	1 (20.0)
Level of education						
Master's degree and	68 (10.2)	472 (70.7)	128 (19.2)	22 (26.8)	42 (51.2)	18 (22.0)
higher						
Bachelor's degree	204 (16.5)	815 (65.9)	218 (17.6)	14 (23.0)	38 (62.3)	9 (14.8)
Secondary/high	49 (11.2)	311 (71.3)	76 (17.4)	3 (33.3)	4 (44.4)	2 (22.2)
school						
Primary/no school	19 (38.0)	29 (58.0)	2 (4.0)	0 (0.0)	1 (50.0)	1 (50.0)
Occupation						
Non-healthcare	157 (9.0)	1,188 (71.2)	313 (18.9)	17 (17.9)	61 (64.2)	17 (17.9)
Healthcare	183 (25.0)	439 (59.9)	111 (15.1)	22 (37.3)	24 (40.7)	13 (19.5)
Working status						
Employed	262 (15.1)	1,149 (66.3)	322 (18.5)	38 (27.3)	76 (54.7)	25 (18.0)
Unemployed	78 (11.9)	478 (72.6)	102 (15.5)	1 (6.7)	9 (60.0)	5 (33.3)
Marital/family status						
Married	126 (12.2)	719 (69.8)	185 (18.0)	29 (31.5)	47 (51.1)	16 (17.4)
Not married #	214 (15.7)	908 (66.7)	239 (17.6)	10 (16.1)	38 (61.3)	14 (22.6)
Religion						
Christians	304 (14.2)	1,439 (67.2)	397 (18.6)	35 (25.4)	78 (56.5)	25 (18.1)
Others	36 (14.3)	188 (74.9)	27 (10.8)	4 (25.0)	7 (43.8)	5 (31.3)
Smoking status						
Ex-smoker	21 (14.8)	98 (69.0)	23 (16.2)	4 (22.2)	13 (72.2)	1 (5.6)

-						
Current smoker	20 (11.9)	113 (67.3)	35 (20.8)	1 (12.5)	5 (62.5)	2 (25.0)
Non-smoker	299 (14.4)	1,627 (68.1)	424 (17.7)	34 (26.6)	67 (52.3)	27 (21.1)
Have you been						
vaccinated for any						
condition						
No	30 (7.0)	326 (75.8)	74 (17.2)	3 (20.0)	9 (60.0)	3 (20.0)
Yes	310 (14.2)	1,301 (66.3)	350 (17.9)	36 (25.9)	76 (54.7)	27 (19.4)
Any pre-existing						
conditions [§]						
No	280 (13.9)	1,383 (68.4)	359 (17.6)	23 (21.5)	61 (57.0)	23 (21.5)
Yes	60 (16.3)	244 (66.1)	65 (17.6)	16 (34.0)	24 (51.1)	7 (14.9)
Knowledge*	18.7 ± 4.9	18.5 ± 6.3	19.6 ± 3.6	22.7 ±	18.9 ± 6.0	20.5 ± 3.8
3				3.4		
Attitude*	1.2 ± 2.2	0.9 ± 2.1	1.0 ± 2.0	0.7 ± 1.9	0.7 ± 1.8	1.3 ± 2.2
Perception*	6.7 ± 2.7	5.6 ± 3.1	5.8 ± 2.3	7.2 ± 2.4	5.3 ± 3.1	5.9 ± 2.9

302 303

Data presented in frequencies (percentages). *Data presented as mean \pm standard deviation. *includes single, divorced and widowed.* [§]includes the presence of any of the following conditions: cancer,

diabetes, hypertension, asthma, kidney disease, any heart condition, sickle cell anemia.

304 305

306

Unadjusted analysis of factors associated with COVID-19 vaccine 307 uptake, resistance and hesitancy in SSA 308

Table 3 shows the unadjusted relative risk of factors associated with resistance and 309

hesitancy towards COVID-19 vaccination among SSA respondents living locally and in the 310

diaspora. Among the local residents, female sex was associated with the COVID-19 vaccine 311

resistance [RR=0.73, 95% CI; 0.58 - 0.93]. East and Southern Africa local residents were 312

significantly associated with COVID-19 vaccine resistance [RR=3.05, 95% CI; 1.31 - 7.08 313

and RR=1.49, 95% CI; 1.12 - 2.00 respectively] and hesitancy [RR=4.50, 95% CI; 1.83 -314

11.02 and RR=1.54, 95% CI; 1.09 - 2.19 respectively]. Having primary or less education was 315

also shown to be significantly associated with COVID-19 vaccine resistance [RR=0.22, 95% 316

CI; 0.12 - 0.41] and hesitancy [RR=0.06, 95% CI; 0.01 - 0.25] among local residents. 317

Unemployment was significantly associated with higher risk 318

of vaccine resistance [RR=1.40, 95% CI; 1.06 - 1.84] among local residents. Being 319

unmarried [RR=0.74, 95% CI: 0.58 – 0.95], and having a history of vaccination for other 320

conditions were associated with lower risk of vaccine resistance [RR=0.39, 95% CI; 0.26 -321

0.57] among locals. Also, those with high risk perception scores were significantly less likely 322

15

- 323 to resist [RR=0.88, 95% CI; 0.84 0.92] or be hesitant [RR=0.90, 95% CI; 0.85 0.94] to the
- 324 COVID-19 vaccines.
- For those in diaspora, older age (>38years) [RR=0.13, 95% CI; 0.03 0.65], working
- in healthcare sector [RR=0.32, 95% CI; 0.25 0.40], having a more knowledge [0.82, 95%
- 327 CI; 0.73 0.91] and better perception scores [RR=0.77, 95% CI; 0.66 0.90], were
- 328 associated with lower risk of COVID-19 vaccine resistance, while not being married
- 329 [RR=0.74, 95% CI; 0.58 0.95] had a higher risk of being resistant.
- 330

331 Table 3. Relative risk (RR) for factors associated with COVID-19 vaccine uptake,

hesitancy and resistance among SSA locals and diasporas. The base reference was COVID-19 vaccine uptake for all variables.

	LO	CAL	DIAS	PORA
Variable	Resistant RR (95%CI)	Hesitant RR (95%CI)	Resistant RR (95%CI)	Hesitant RR (95%CI)
Age in years				
18 - 28	1.00	1.00	1.00	1.00
29 - 38	0.88 (0.66 - 1.18)	1.18 (0.83 - 1.67)	0.98 (0.15 - 6.50)	2.17 (0.26 - 17.89)
39 - 48	1.06 (0.76 - 1.47)	1.03 (0.68 - 1.55)	0.13 (0.03 - 0.65)	0.22 (0.03 - 1.47)
49+	1.27 (0.84 - 1.92)	1.51 (0.93 - 2.46)	0.17 (0.03 - 0.84)	0.16 (0.02 - 1.12)
Sex				
Males	1.00	1.00	1.00	1.00
Females	0.73 (0.58 - 0.93)	0.83 (0.62 - 1.10)	2.13 (0.83 - 5.43)	1.66 (0.53 - 5.25)
Region				
West Africa	1.00	1.00	1.00	1.00
East Africa	3.05 (1.31 - 7.08)	4.50 (1.83 - 11.02)	-	-
Central Africa	0.73 (0.53 - 1.02)	0.68 (0.44 - 1.05)	1.58 (0.56 - 4.45)	0.51 (0.09 - 2.76)
Southern Africa	1.49 (1.12 - 2.00)	1.54 (1.09 - 2.19)	-	-
Level of education				
Master's degree and	1.00	1.00	1.00	1.00
more				
Bachelor's degree	0.58 (0.43 - 0.77)	0.57 (0.40 - 0.81)	1.42 (0.64 - 3.17)	0.79 (0.28 - 2.23)
Secondary/High	0.91 (0.62 - 1.36)	0.82 (0.52 - 1.31)	0.70 (0.14 - 3.40)	0.81 (0.12 - 5.42)
School				
Primary/Less	0.22 (0.12 - 0.41)	0.06 (0.01 - 0.25)	-	-
Occupation				
Non-healthcare	1.00	1.00	1.00	1.00
Healthcare	0.32 (0.25 - 0.40)	0.30 (0.22 - 0.41)	0.30 (0.14 - 0.67)	0.59 (0.23 - 1.54)
Working status				
Employed	1.00	1.00	1.00	1.00
Unemployed	1.40 (1.06 - 1.84)	1.06 (0.76 - 1.49)	4.0 (0.55 - 36.83)	7.60 (0.84 - 68.97)
Marital/family status				
Married	1.00	1.00	1.00	1.00
Not married #	0.74 (0.58 - 0.95)	0.76 (0.57 - 1.02)	2.34 (1.02 - 5.41)	2.54 (0.92 - 7.00)
Religion				
Christians	1.00	1.00	1.00	1.00
Others	1.10 (0.76 - 1.61)	0.57 (0.34 - 0.97)	0.79 (0.22 - 2.86)	1.75 (0.43 - 7.18)

Smoking status				
Ex-smoker	1.00	1.00	1.00	1.00
Current smoker	1.21 (0.62 - 2.36)	1.60 (0.71 - 3.58)	1.54 (0.14 - 17.33)	8.0 (0.31 - 206.37)
Non-smoker	1.01 (0.62 - 1.65)	1.12 (0.61 - 2.06)	0.61 (0.18 - 2.00)	3.18 (0.34 - 30.10)
Have you been				
vaccinated for any				
condition				
No	1.00	1.00	1.00	1.00
Yes	0.39 (0.26 - 0.57)	0.46 (0.29 - 0.72)	0.70 (0.18 - 2.76)	0.75 (0.14 - 4.01)
Any pre-existing				
conditions [§]				
No	1.00	1.00	1.00	1.00
Yes	0.82 (0.60 - 1.12)	0.84 (0.58 - 1.24)	0.57 (0.26 - 1.25)	0.44 (0.15 - 1.26)
Knowledge	0.99 (0.97 - 1.01)	1.03 (1.01 - 1.06)	0.82 (0.73 - 0.91)	0.87 (0.77 - 0.98)
Attitude	0.96 (0.91-1.01)	0.96 (0.90 - 1.03)	0.99 (0.80 - 1.24)	1.15 (0.90 -1.46)
Perception	0.88 (0.84 - 0.92)	0.90 (0.85 - 0.94)	0.77(0.66 - 0.90)	0.84 (0.70 - 1.01)

335 If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against 336 vaccinated pregnant women (RR=1.0).

337 *includes single, divorced, and widowed.*

[§]includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney 338

339 disease, any heart condition, sickle cell anemia

340

Adjusted analysis of factors associated with COVID-19 vaccine 341 uptake, resistance and hesitancy in SSA 342

Table 4 presents the associated factors of COVID-19 vaccine resistance and hesitancy 343

in this study. After controlling for potential confounders in the local resident group, East 344

African respondents were more likely to be resistant [ARR= 3.33, 95% CI: 1.40 - 7.94] and 345

hesitant [ARR= 4.64, 95% CI; 1.84 - 11.70] towards receiving COVID-19 vaccines while 346

Central African respondents were less likely to be resistant [ARR= 0.46, 95% CI; 0.32 - 0.68] 347

or hesitant [ARR= 0.44, 95%CI: 0.27 - 0.72] towards the vaccines. Having a bachelor's 348

degree [ARR= 0.54, 95% CI; 0.38 - 0.76] or lower, being a health care worker [ARR= 0.24, 349

95% CI; 0.18 - 0.32], being previously vaccinated for any condition [ARR= 0.45, 95% CI; 350

- 0.30 0.69], and having a lower risk perception score [ARR= 0.86, 95% CI; 0.82 0.90] 351
- were associated with reduced risk of being resistant towards the COVID-19 vaccines among 352
- local residents in SSA. Among those in the diaspora, respondents who were aged 49 years 353
- and older [ARR= 0.17, 95% CI; 0.03 0.95], those who work in healthcare sectors [ARR= 354

17

- 0.25, 95% CI; 0.10 0.62], as well as those with lower knowledge scores [ARR= 0.82, 95%] 355
- CI: 0.73 0.91 were less likely to resist taking the COVID-19 vaccines. 356

357 Table 4: Adjusted Relative Risk (ARR) for factors associated with vaccine hesitancy among SSA residents living in (Locals) and outside of Africa (Diaspora). The base 358

reference was COVID-19 vaccine uptake for all variables. 359

360

		ocal	Diaspora		
Variable	Resistant	Hesitant	Resistant	Hesitant	
	ARR (95%CI)	ARR (95%CI)	ARR (95%CI)	ARR (95% CI)	
18 – 28 years	1.00	1.00	1.00	1.00	
29 – 38 years	1.32 (0.94 - 1.85)	1.89 (1.26 - 2.84)	1.35 (0.18 - 10.07)	2.6 (0.30 - 23.17)	
39 – 48 years	1.28 (0.867 - 1.89)	1.29 (0.80 - 2.07)	0.21 (0.04 - 1.17)	0.29 (0.04 - 2.08)	
49 + years	1.39 (0.86 - 2.23)	1.74 (1.00 - 3.05)	0.17 (0.03 - 0.95)	0.15 (0.02 - 1.16)	
West Africa	1.00	1.00	-	-	
East Africa	3.33 (1.40 - 7.94)	4.64 (1.84 - 11.70)	-	-	
Central Africa	0.46 (0.32 - 0.68)	0.44 (0.27 - 0.72)	-	-	
Southern Africa	1.32 (0.94 - 1.84)	1.39 (0.94 - 2.06)	-	-	
Master's & above	1.00	1.00	-	-	
Bachelor's degree	0.54 (0.38 - 0.76)	0.60 (0.40 - 0.90)	-	-	
Secondary/ high	0.52 (0.31 - 0.87)	0.56 (0.31 - 1.02)	-	-	
School					
Primary & Less	0.15 (0.07 - 0.32)	0.05 (0.01 - 0.24)	-	-	
Non-health care	1.00	1.00	1.00	1.00	
Health care	0.24 (0.18 - 0.32)	0.19 (0.13 - 0.27)	0.25 (0.10 - 0.62)	0.46 (0.16 - 1.35)	
Christians	1.00	1.00	-	-	
Others	0.96 (0.64 - 1.46)	0.50 (0.29 - 0.86)	-	-	
Vaccinated for any	0.45 (0.30 - 0.69)	0.48 (0.29 - 0.77)	-	-	
condition					
Knowledge	1.02 (1.00 - 1.05)	1.07 (1.04 – 1.11)	0.82 (0.73 – 0.91)	0.88 (0.77 - 0.99)	
Perception	0.86 (0.82 - 0.90)	0.85 (0.80 - 0.90)	-	-	

361 If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against 362 vaccinated pregnant women (RR=1.0).

363

364 Regarding COVID-19 vaccine hesitancy among local residents in SSA, the significant factors included East and Central African origin, aged between 29 – 38 years, being a health 365 care worker, having a bachelor's degree or less, non-Christians, having been previously 366 vaccinated for other conditions, higher knowledge and lower perception scores. While for 367 those in diaspora being a health care worker [ARR= 0.46, 95% CI; 0.16 - 1.35] and having 368 lower knowledge scores [ARR= 0.88, 95% CI; 0.77 - 0.99] were the factors that were 369 significant for being hesitant. 370

18

372 **Discussion**

The purpose of this study was to compare the uptake, resistance and hesitancy of the 373 COVID-19 vaccine between the local residents and diaspora dwellers in SSA region of the 374 African continent. Uptake of the COVID-19 vaccine was found to be twice as high among 375 residents in the diaspora compared to local SSA residents. The WHO and Centers for Disease 376 Control and Prevention (CDC) have suggested that the low vaccination rates in low-and-377 middle-income countries is in part, due to inequitable distribution of vaccines. Accessibility 378 to vaccines may have played a role in the low uptake rates in our study. At the time of the 379 study, half of the 52 African countries that had received vaccines had only vaccinated up to 380 2% of their population at the time of this study, and 15 countries had vaccinated up to 381 10%.[42] However, majority of those residing in Africa and the diaspora were either resistant 382 383 or hesitant to get vaccinated. This finding is different from that reported in a previous study [43] where a higher proportion of African residents and those in the diaspora were willing to 384 385 accept the vaccine when offered. A survey conducted by CDC Africa prior to the introduction of vaccines on the continent found that the willingness to take the vaccine in 15 African 386 countries ranged from 59% to 93%, [44] which was in contrast with our findings of greater 387 resistance towards COVID-19 vaccination. Studies conducted in the US and UK showed that 388 Africans/Blacks were 13 times more likely to be hesitant than Whites [45-46] which is similar 389 to the high proportions of SSA in diaspora who were either hesitant or resistant to taking 390 COVID-19 vaccines. 391

Socio-demographic characteristics have been shown to play significant roles in
vaccine hesitancy and resistance.[46] In this study, age, region of origin, educational level,
occupation and religion were significantly associated with either vaccine hesitancy or
resistance among local and diaspora residents. Younger age groups among the local residents

19

were almost twice likely to be hesitant and older age groups were less likely to be resistant to vaccines. This finding is consistent with other previous studies,[32,37,46-47] and may also be related to the fact that COVID-19 is more likely to present in the severe form among older age groups, making them more likely to accept the vaccine for their protection.

400 Local East African respondents were three times more likely to resist and almost five times more likely to be hesitant than West Africans. This may be due to misinformation about 401 COVID-19 [48] and its vaccines [49] which was reported to be more common in East African 402 countries such as Tanzania. The results showed that the least educated respondents were less 403 404 likely to be resistant or hesitant. This may be as a result of not comprehending the scientific arguments being advanced against the vaccines and having to make choices based on past 405 experiences or the information they do understand. A recent study in the US showed a similar 406 pattern with those with lower levels of education showing less hesitancy than those with 407 higher.[49] This is contrary to the results obtained in other studies.[35-37,42-43] A statement 408 409 by a 61 year old on Africa news may provide an insight into the mindset of those who are less educated thereby making them more likely to accept vaccination: "If in the time of our 410 mothers, in the time we were little children if these "WhatsApp doctors" had existed (people 411 who post unreliable medical information on social media) I think we would have all died 412 because our mothers who did not go to school agreed to vaccinate us against smallpox, 413 measles, polio -- all the other diseases without debate. Today, we are more educated, but 414 curiously, we refuse vaccination. This is a certain danger for our society, according to what I 415 have read here and there. The Congo is being blacklisted because we risk many deaths if we 416 417 don't accept vaccination".[50]

Both local and diaspora healthcare workers showed less likelihood of being either
resistant or hesitant as compared to non-healthcare workers in this study. Resistance and

20

hesitancy have been found among health workers though lower when compared to non-420 healthcare workers. [50-55] However, Blacks /African health workers still show higher risk 421 than their counterparts of being resistant/hesitant irrespective of the country they are in. 422 Vaccine resistance and/or hesitancy is a hindrance to the vaccination campaign, as such, 423 health workers who should be well educated about the vaccines are likely to exert an 424 influence on others and possibly deter them from getting vaccinated. Most findings in the 425 426 cited papers found that the fear of side effects was usually the reason for hesitancy and resistance among health workers. [51-53] 427

Among the local residents, individuals form other religions were less likely to be 428 vaccine hesitant compared to those of the Christian faith. Religion has been reported to play a 429 huge role in the life of Africans and influences their health seeking behavior. [57-58] Olagoke 430 et al. reported that some religious views have contributed to the rejection of vaccination.[59] 431 However, an intervention study conducted among American Christians, [60] showed that with 432 proper presentation of scientific facts, such negative views can be changed. Community 433 engagement with religious leaders has also been advocated as a means of addressing vaccine 434 hesitancy.[61] 435

Local residents who had been previously vaccinated for other conditions were less 436 likely to be COVID-19 vaccine resistant or hesitant. This finding emphasizes the influence of 437 past experiences which can build confidence in the efficacy of vaccines. Other studies have 438 also shown a willingness to be vaccinated among those who had previously received 439 vaccinations for other diseases such as flu, yellow fever, hepatitis.[62-63] Knowledge of 440 441 COVID-19 vaccine was a significant factor among both local and diaspora residents. Knowledge has been shown to reduce resistance to vaccine acceptance. Africans in the 442 diaspora were less likely to be hesitant or resistant to vaccines as compared to their 443

21

counterparts residing in Africa. This may still be related to misinformation and the need for 444 health messages to be relayed in the languages familiar to the people. Recent studies have 445 shown a decline in those who are hesitant and this has been attributed to the availability of 446 accurate information that reduces fear and leads to making informed decisions.[64] Exposure 447 to accurate information and increased knowledge about COVID-19 vaccines may help those 448 who are hesitant to be more receptive to vaccines. Among local residents, higher perception 449 scores showed a lower odd of being either resistant or hesitant. The perception that one is 450 likely to be at risk of contracting a disease can result in people taking appropriate measures to 451 452 protect themselves from contracting the disease.

453 Strengths and limitations

This is the first large scale study to compare acceptance of COVID-19 vaccines 454 between sub-Saharan African local residents and those in the diaspora. The study employed 455 robust analyses to control for potential confounders to reduce the possibility of a bias. The 456 distribution of the questionnaire in both English and French languages using an internet-457 based methodology, which was the only reliable means to disseminate information at the time 458 of this study to a wider audience. Notwithstanding these strengths, the study has some 459 limitations. For example, the study did not explore concerns about vaccine safety which may 460 be an important determinant of vaccine hesitancy. The cross-sectional nature of the study 461 means that causation cannot be determined. The survey was distributed electronically using 462 social media platforms and emails, and this may have inadvertently excluded some potential 463 participants whose opinions may have differed, such as those without internet access and 464 people living in rural areas, where internet penetration remains relatively low.[65] The survey 465 was presented in English and French and thus inadvertently excluding some of the 466 Portuguese or Arabic-speaking SSA countries from participating. Although the study showed 467

22

satisfactory internal validity, its generalization or transferability to all SSA countries may belimited.

470 **Conclusion**

471	The study showed that Africans residing both locally and in diaspora are mostly either
472	resistant or hesitant to the COVID-19 vaccines. Factors that influenced resistance and
473	hesitancy among local residents included younger age, being from East and Central Africa,
474	lower levels of education, history of previous vaccinations, being a health care worker,
475	knowledge and perceptions of COVID-19 vaccine. For Africans in the diaspora, being
476	hesitant or resistant to COVID-19 vaccines are influenced by older age, being a health care
477	worker and having adequate knowledge of vaccines. Appropriate interventions such as public
478	health messaging are required to enhance COVID-19 uptake to achieve sufficient vaccine
479	coverage.

480 Acknowledgement: None to acknowledge.

481

482 **References**

484	1.	Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic
485		in history. Biomed J. 2020 Aug; 43(4):328-33. doi: 10.1016/j.bj.2020.04.007. Epub
486		2020 May 5. PubMed PMID: 32387617; PubMed Central PMCID: PMC7199674.
487	2.	Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ et al. Comparison of the
488		second and third waves of the COVID-19 pandemic in South Korea: Importance of
489		early public health intervention. Int J Infect Dis. 2021 Mar; 104:742-5. doi:
490		10.1016/j.ijid.2021.02.004. Epub 2021 Feb 5. PubMed PMID: 33556610; PubMed
491		Central PMCID: PMC7863747.

492	3.	Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M et al. The first
493		and second waves of the COVID-19 pandemic in Africa: a cross-sectional study.
494		Lancet. 2021 Apr 3; 397(10281):1265-75. doi: 10.1016/S0140-6736(21)00632-2.
495		Epub 2021 Mar 24. PubMed PMID: 33773118; PubMed Central PMCID:
496		PMC8046510.
497	4.	Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics
498		and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron
499		wave compared with previous waves. JAMA. 2022 Feb 8; 327(6):583-4. doi:
500		10.1001/jama.2021.24868. PubMed PMID: 34967859; PubMed Central PMCID:
501		PMC8719272.
502	5.	Grabowski F, Kochańczyk M, Lipniacki T. The spread of SARS-CoV-2 variant
503		Omicron with a doubling time of 2.0–3.3 days can be explained by immune evasion.
504		Viruses. 2022; 14(2):294. https://doi.org/10.3390/v14020294.
505	6.	Brandal LT., MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U et al. Outbreak
506		caused by the SARS-CoV-2 Omicron variant in Norway, November to December
507		2021. Euro Surveill. 2021; 26 (50). pii=2101147. https://doi.org/10.2807/1560-
508		7917.ES.2021.26.50.2101147.
509	7.	Helmsdal G, Hansen OK, Møller LF, Christiansen DH, Petersen MS, Kristiansen MF.
510		Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-
511		vaccinated healthcare workers. Clin Infect Dis. 2022 Feb 3:ciac089. doi:
512		10.1093/cid/ciac089. Epub ahead of print. PubMed PMID: 35134167.
513	8.	Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK et al.
514		Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern
515		and its global perspective. J Med Virol. 2022 Apr; 94(4):1738-44. doi:
516		10.1002/jmv.27524. Epub 2022 Jan 11. Pub Med PMID: 34905235.

517	9.	Odusanya OO, Odugbemi BA, Odugbemi TO, Ajisegiri WS. COVID-19: A review of
518		the effectiveness of non-pharmacological interventions. Niger Postgrad Med J. 2020;
519		27(4)261-7.
520	10	. Gokmen Y, Baskici C, Ercil Y. Effects of non-pharmaceutical interventions against
521		COVID-19: A cross-country analysis. Int J Health Plann Manage. 2021 Jul;
522		36(4):1178-88. doi: 10.1002/hpm.3164. Epub 2021 Apr 5. PubMed PMID: 33819370;
523		PubMed Central PMCID: PMC8251211.
524	11	. Schuchat A. Human vaccines and their importance to public health. Procedia
525		Vaccinol 2011; 5: 120-6.
526	12	. World Health Organization [Internet]. Draft landscape and tracker of COVID-19
527		candidate vaccines; c2020 [cited 2022 Jan 23]. Available from:
528		https://www.who.int/docs/default-source/a-future-for-children/novel-
529		coronavirus_landscape_covid-19.pdf?sfvrsn=4d8bd201_1.
530	13	. World Health Organization [Internet]. Guidance document: Status of COVID-19
531		Vaccines within WHO EUL/PQ evaluation process; c2022 [cited 2021 May 20].
532		Available from:
533		https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02
534		March2022.pdf.
535	14	. National Research Council (US) Division of Health Promotion and Disease
536		Prevention. Vaccine Supply and Innovation. Washington (DC): National Academies
537		Press (US); c1985 [cited 2021 may 21] 3, Vaccine Availability: Concerns, Barriers,
538		and Impediments. Available from: https://www.ncbi.nlm.nih.gov/books/NBK216807/.
539	15	. Valckx S, Crèvecoeur J, Verelst F, Vranckx M, Hendrickx G, Hens N et al. Individual
540		factors influencing COVID-19 vaccine acceptance in between and during pandemic
541		waves (July-December 2020). Vaccine. 2022 Jan 3; 40(1):151-61. doi:

542	10.1016/j.vaccine.2021.10	0.073. Epub 2021 Dec	1. Pubmed PMID: 34863621;
-----	---------------------------	----------------------	---------------------------

543 PubMed Central PMCID: PMC8634074..

- 16. Mustapha M, Lawal BK, Sha'aban A, Jatau AI, Wada AS, Bala AA et al. Factors
- associated with acceptance of COVID-19 vaccine among University health sciences
- students in Northwest Nigeria. PLoS One. 2021 Nov 29;16(11):e0260672. doi:
- 547 10.1371/journal.pone.0260672. PubMed PMID: 34843594; PubMed Central PMCID:
 548 PMC8629299.
- 549 17. Kamal AHM, Sarkar T, Khan MM, Roy SK, Khan SH, Hasan SMM et al. Factors
- affecting willingness to receive COVID-19 vaccine among adults: a cross-sectional
- study in Bangladesh. Journal of Health Management.2021 Oct. doi:
- 55210.1177/09735984211050691.
- 18. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the
 elephant (not) in the room. Lancet Microbe. 2021 Jul; 2(7):e279-e280. doi:
- 555 10.1016/S2666-5247(21)00069-0. Epub 2021 Apr 20. PubMed PMID: 33899038;
 556 PubMed Central PMCID: PMC8057721.
- 557 19. Cho W, Kirwin MF [Internet]. WP71: A vicious circle of corruption and mistrust in
 558 institutions in sub-Saharan Africa: a micro-level analysis. Afrobarometer; c2007
- 559 [cited 2022 Jan 23]. Available from: https://afrobarometer.org/publications/wp71-
- 560 vicious-circle-corruption-and-mistrust-institutions-sub-saharan-africa-micro-level.
- 20. Razai MS, Chaudhry U A R, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination
 hesitancy BMJ. 2021; 373:n1138. doi:10.1136/BMJ.n1138.
- 563 21. World Health Organization [Internet]. Ten threats to global health in 2019; c2019
- 564 [cited 2022 Jan 23]. Available from: https://www.who.int/news-room/spotlight/ten565 threats-to-global-health-in-2019.
- 566 22. Geoghegan S, O'Callaghan KP, Offit PA. Vaccine safety: myths and misinformation.

567		Front Microbiol. 2020 Mar 17; 11:372. doi: 10.3389/fmicb.2020.00372. PubMed
568		PMID: 32256465; PubMed Central PMCID: PMC7090020.
569	23.	Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and
570		resistance in India explored through a population-based longitudinal survey. Vaccines
571		(Basel). 2021 Sep 24; 9(10):1064. doi: 10.3390/vaccines9101064. PubMed PMID:
572		34696172; PubMed Central PMCID: PMC8537475.
573	24.	Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ.
574		COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J
575		Community Health. 2021 Apr; 46(2):270-7. doi: 10.1007/s10900-020-00958-x. Epub
576		2021 Jan 3. PubMed PMID: 33389421; PubMed Central PMCID: PMC7778842.
577	25.	Kini A, Morgan R, Kuo H, Shea P, Shapiro J, Leng SX et al. Differences and
578		disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage
579		by age, sex, gender, and race. Vaccine. 2022 Mar 8; 40(11):1643-54. doi:
580		10.1016/j.vaccine.2021.04.013. Epub 2021 Apr 28. PubMed PMID: 33933316;
581		PubMed Central PMCID: PMC8551304.
582	26.	Niederhauser VP, Stark M. Narrowing the gap in childhood immunization disparities.
583		Pediatr Nurs. 2005 Sep-Oct; 31(5):380-6. PubMed PMID: 16295153.
584	27.	Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine
585		hesitancy and equitable diffusion of effective COVID-19 vaccines. J Gen Intern Med.
586		2021 Jul; 36(7):2130-3. doi: 10.1007/s11606-021-06698-5. Epub 2021 Mar 22.
587		PubMed PMID: 33754319; PubMed Central PMCID: PMC7985226.
588	28.	Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine
589		acceptance in the US. EClinicalMedicine. 2020 Sep; 26:100495. doi:
590		10.1016/j.eclinm.2020.100495. Epub 2020 Aug 12. PubMed PMID: 32838242;
591		PubMed Central PMCID: PMC7423333.

592	29. The ICD "Experience Africa" Program [Internet]. The African Diaspora. Introduction
593	to the African Diaspora across the World; c2021 [cited 2022 Jan 23]. Available from:
594	https://www.experience-africa.de/index.php?en_the-african-diaspora.
595	30. African Diaspora [Internet]. Meeting of Experts on the Definition of the African
596	Diaspora 11 – 12 April 2005 Addis Ababa, Ethiopia. Report of the meeting of experts
597	from members of States on the definition of African Diaspora; c2021 [cited 2022 Jan
598	23]. Available from: http://www.dirco.gov.za/diaspora/definition.html.
599	31. Riesen M, Konstantinoudis G, Lang P, Low N, Hatz C, Maeusezahl M et al.
600	Exploring variation in human papillomavirus vaccination uptake in Switzerland: a
601	multilevel spatial analysis of a national vaccination coverage survey. BMJ Open.
602	2018 May 17; 8(5):e021006. doi: 10.1136/bmjopen-2017-021006. PubMed PMID:
603	29773702; PubMed Central PMCID: PMC5961588.
604	32. McAuslane H, Utsi L, Wensley A, Coole L, Inequalities in maternal pertussis
605	vaccination uptake: a cross-sectional survey of maternity units, J Public Health. 2018
606	Mar; 40(1):121-8. doi: https://doi.org/10.1093/pubmed/fdx032.
607	33. Basak P, Abir T, Al Mamun A, Zainol NR, Khanam M, Haque MR et al. A global
608	study on the correlates of Gross Domestic Product (GDP) and COVID-19 vaccine
609	distribution. Vaccines. 2022; 10(2):266. doi:
610	https://doi.org/10.3390/vaccines10020266.
611	34. World Health Organization [Internet]. Africa on track to control COVID-19 pandemic
612	in 2022; c2022 [cited 2022 Jan 23]. Available from:
613	https://www.afro.who.int/news/africa-track-control-covid-19-pandemic-2022.
614	35. World Health Organization Regional Office for Africa [Internet]. Risks and
615	challenges in Africa's COVID-19 vaccine rollout; c2021 [cited 2022 Jan 23]
616	Available from: https://www.afro.who.int/news/risks-and-challenges-africas-covid-

28

617 19-vaccine-rollout.

618	36. Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19 vaccine roll-out in South
619	Africa and Zimbabwe: urgent need to address community preparedness, fears and
620	hesitancy. Vaccines. 2021; 9(3):250. doi: https://doi.org/10.3390/vaccines9030250.
621	37. Abu EK, Oloruntoba R, Osuagwu UL, Bhattarai D, Miner CA, Goson PC et al. Risk
622	perception of COVID-19 among sub-Sahara Africans: a web-based comparative
623	survey of local and diaspora residents. BMC Public Health. 2021 Aug 18; 21(1):1562.
624	doi: 10.1186/s12889-021-11600-3. PubMed PMID: 34404377; PubMed Central
625	PMCID: PMC8370831.
626	38. World Medical Assembly [Internet]. WMA Declaration of Helsinki - Ethical
627	Principles for Medical Research Involving Human Subjects. c2013 [cited 2022 Jan
628	23]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-
629	ethical-principles-for-medical-research-involving-human-subjects/.
630	39. Geldsetzer P. Use of rapid online surveys to assess people's perceptions during
631	infectious disease outbreaks: a cross-sectional survey on COVID-19. J Med Internet
632	Res. 2020 Apr 2; 22(4):e18790. doi: 10.2196/18790. Pubmed PMID: 32240094;
633	PubMed Central PMCID: PMC7124956.
634	40. Biasio LR, Bonaccorsi G, Lorini C, Pecorelli S. Assessing COVID-19 vaccine
635	literacy: a preliminary online survey. Hum Vaccin Immunother. 2021 May
636	4;17(5):1304-12. doi: 10.1080/21645515.2020.1829315. Epub 2020 Oct 29. PubMed
637	PMID: 33118868; PubMed Central PMCID: PMC8078752.
638	41. Buzasi K. Linguistic Situation in Twenty sub-Saharan African Countries: A Survey-
639	based Approach. Afr Stud. 2016; 75:358-80. doi: 10.1080/00020184.2016.1193376
640	42. World Health Organization Regional Office for Africa [Internet]. Fifteen African
641	countries hit 10% COVID-19 vaccination goal; c2021 [cited 2022 Jan 23]. Available

from: https://www.afro.who.int/news/fifteen-african-countries-hit-10-covid-19-

642

643	vaccination-goal.
644	43. Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris BF, et al.
645	Will Africans take COVID-19 vaccination? PLoS ONE. 2021; 16(12): e0260575. doi:
646	https://doi.org/10.1371/journal.pone.0260575.
647	44. Africa Centers for Disease Control and Prevention [Internet]. COVID 19 vaccine
648	perceptions: A 15 country study; c2021 [cited 2022 Jan 23]. Available from:
649	https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/.
650	45. Momplaisir FM, Kuter BJ, Ghadimi F, Browne S, Nkwihoreze H, Feemster KA et al.
651	Racial/ethnic differences in COVID-19 vaccine hesitancy among health care workers
652	in 2 large academic hospitals. JAMA Netw Open. 2021 Aug 2; 4(8):e2121931. doi:
653	10.1001/jamanetworkopen.2021.21931. PubMed PMID: 34459907; PubMed Central
654	PMCID: PMC8406078.
655	46. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M et al.
656	Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study.
657	Brain Behav Immun. 2021 May; 94:41-50. doi: 10.1016/j.bbi.2021.03.008. Epub
658	2021 Mar 11. PubMed PMID: 33713824; PubMed Central PMCID: PMC7946541.
659	47. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO et al. Hesitant or not?
660	The association of age, gender, and education with potential acceptance of a COVID-
661	19 vaccine: a country-level analysis. J Health Commun. 2020 Oct 2;25(10):799-807.
662	doi: 10.1080/10810730.2020.1868630. PubMed PMID: 33719881.
663	48. Osuagwu UL, Miner CA, Bhattarai D, Mashige KP, Oloruntoba R, Abu EK et al.
664	Misinformation about COVID-19 in sub-Saharan Africa: evidence from a cross-
665	sectional survey. Health Secure. 2021 Jan-Feb;19(1):44-56. DOI:
666	10.1089/HS.2020.0202. PMID: 33606572.

667	49.	. King WC, Rubinstein M, Reinhart A, Mejia R. Time trends, factors associated with,
668		and reasons for COVID-19 vaccine hesitancy: A massive online survey of US adults
669		from January-May 2021. PLoS One. 2021 Dec 21; 16(12):e0260731. doi:
670		10.1371/journal.pone.0260731. PubMed PMID: 34932583; PubMed Central PMCID:
671		PMC8691631.
672	50.	Asala K; Africanews [Internet]. DR Congo: COVID-19 vaccine hesitation amid
673		surging cases in third wave. [cited 2022 Feb 21]. Available from:
674		https://www.africanews.com/2021/07/02/dr-congo-covid-19-vaccine-hesitation-amid-
675		surging-cases-in-third-wave//.
676	51.	. Toth-Manikowski SM, Swirsky ES, Gandhi R, Piscitello G. COVID-19 vaccination
677		hesitancy among health care workers, communication, and policy-making. Am J
678		Infect Control. 2022 Jan; 50(1):20-5. doi: 10.1016/j.ajic.2021.10.004. Epub 2021 Oct
679		13. PubMed PMID: 34653527; PubMed Central PMCID: PMC8511871.
680	52.	. Amuzie CI, Odini F, Kalu KU, Izuka M, Nwamoh U, Emma-Ukaegbu U et al.
681		COVID-19 vaccine hesitancy among healthcare workers and its socio-demographic
682		determinants in Abia State, Southeastern Nigeria: a cross-sectional study. Pan Afr
683		Med J. 2021 Sep 3; 40:10. doi: 10.11604/pamj.2021.40.10.29816. PubMed PMID:
684		34650660; PubMed Central PMCID: PMC8490164
685	53.	Aoun AH, Aon MH, Alshammari AZ, Moussa SA. COVID-19 vaccine hesitancy
686		among health care workers in the Middle East Region. Open Public Health J. 2021;
687		14: 352–9. doi: 10.2174/1874944502114010352.
688	54.	Angelo AT, Alemayehu DS, Dachew AM. Health care workers intention to accept
689		COVID-19 vaccine and associated factors in southwestern Ethiopia. 2021. PLoS One.
690		2021 Sep 3; 16(9):e0257109. doi: 10.1371/journal.pone.0257109. PubMed PMID:
691		34478470; PubMed Central PMCID: PMC8415602.

692	55. Ashok N, Krishnamurthy K, Singh K, Rahman S, Majumder MAA. High COVID-19
693	Vaccine Hesitancy Among Healthcare Workers: Should Such a Trend Require Closer
694	Attention by Policymakers? Cureus. 2021 Sep 15; 13(9):e17990. doi:
695	10.7759/cureus.17990. PubMed PMID: 34667668; PubMed Central PMCID:
696	PMC8519358.
697	56. Algabbani F, Algabbani A. Vaccine hesitancy among healthcare providers during
698	COVID-19 pandemic. Eur J Public Health. 2021; 31 Suppl_7. doi:
699	https://doi.org/10.1093/eurpub/ckab164.101
700	57. Wirsiy FS, Nkfusai CN, Ako-Arrey DE, Dongmo EK, Manjong FT, Cumber SN.
701	Acceptability of COVID-19 Vaccine in Africa. Int J MCH AIDS. 2021; 10(1):134-8.
702	doi: 10.21106/ijma.482. Epub 2021 Apr 8. PubMed PMID: 33868778; PubMed
703	Central PMCID: PMC8039868.
704	58. Costa JC, Weber AM, Darmstadt GL, Abdalla S, Victora CG. Religious affiliation
705	and immunization coverage in 15 countries in Sub-Saharan Africa. Vaccine. 2020 Jan
706	29; 38(5):1160-9. doi: 10.1016/j.vaccine.2019.11.024. Epub 2019 Nov 30. PubMed
707	PMID: 31791811; PubMed Central PMCID: PMC6995994.
708	59. Olagoke AA, Olagoke OO, Hughes AM. Intention to vaccinate against the novel 2019
709	coronavirus disease: the role of health locus of control and religiosity. J Relig Health.
710	2021 Feb; 60(1):65-80. doi: 10.1007/s10943-020-01090-9. Epub 2020 Oct 30.
711	PubMed PMID: 33125543; PubMed Central PMCID: PMC7596314.
712	60. Chu J, Pink SL, Willer R. Religious identity cues increase vaccination intentions and
713	trust in medical experts among American Christians. Proc Natl Acad Sci U S A. 2021
714	Dec 7; 118(49):e2106481118. doi: 10.1073/pnas.2106481118. PubMed PMID:
715	34795017; PubMed Central PMCID: PMC8670469.

61. Melillo S, Fountain D, Bormet M, O'Brien CJ; MOMENTUM Country and Global

32

717	Leadership. Effects of faith actor engagement in the uptake and coverage of
718	immunization in low- and middle-income countries (LMICs)* Phase 1 Global
719	Landscape : Evidence Summary. c2021 [cited 2022 Jan 24]. Available from:
720	https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-
721	Immunization_Global-Landscape-Analysis_Evidence-Summary-Report_June-
722	2021_Sec508comp-low.pdf.
723	62. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ.
724	Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from
725	Jordan. PLoS One. 2021 Apr 23; 16(4):e0250555. doi:
726	10.1371/journal.pone.0250555. PubMed PMID: 33891660; PubMed Central PMCID:
727	PMC8064595.
728	63. Wake AD. The willingness to receive COVID-19 vaccine and its associated factors:
729	"Vaccination refusal could prolong the war of this pandemic" - a systematic review.
730	Risk Manag Healthc Policy. 2021 Jun 21; 14:2609-2623. doi:
731	10.2147/RMHP.S311074. PubMed PMID: 34188572; Pubmed Central PMCID:
732	PMC8232962.
733	64. Siegler AJ, Luisi N, Hall EW, Bradley H, Sanchez Z, Lopman BA et al. Trajectory of
734	COVID-19 vaccine hesitancy over time and association of initial vaccine hesitancy
735	with subsequent vaccination. JAMA Netw Open. 2021; 4(9): e2126882-e2126882.
736	doi:10.1001/jamanetworkopen.2021.26882.
737	65. Hjort, J, Poulsen, J. The arrival of fast internet and employment in Africa. American
738	Economic Review. 2019; 109(3):1032-79. doi: 10.1257/aer.20161385
739 740	Supporting information
741	S1 Table. Sample of the survey items used in this study

